Substance P Antagonist Peptide
Imagine your joints have a built-in alarm system that's supposed to warn you about damage. Substance P is like the messenger that carries these pain signals through your nervous system. In people with joint problems, this messenger gets overactive and starts amplifying pain way beyond what's actually needed — like a smoke detector that won't stop screaming even after the small fire is out. A Substance P antagonist peptide is basically a blocker that stops this messenger from doing its job, which reduces both the pain itself and the inflammation feeding it.
Here's how it works in your body: When your joints get injured or inflamed, nerve fibers release Substance P into the surrounding tissue. This messenger then latches onto special docking stations called NK1 receptors on various immune and joint cells. Once activated, these cells go into overdrive, releasing inflammatory chemicals and making your nerves even more sensitive to pain. It becomes a vicious cycle where your nervous system keeps amplifying the problem. The antagonist peptide works by blocking those docking stations, so Substance P can't trigger this cascade. By stopping the neurogenic inflammation at its source rather than just drowning out the pain signal, this approach tackles the root cause instead of just masking symptoms.
Dosage Information
Typical Dose
Research compounds — clinical studies ongoing
Frequency
N/A for peptide antagonists
Administration
Intra-articular injection in research
Half-Life
6–12 hours
estimatedNotes
Aprepitant (oral NK1R antagonist) has been studied off-label for OA pain. Peptide-specific NK1R antagonists are in research stage. This entry documents the neurogenic inflammation mechanism in joint pain.
Why this matters
NK1 receptor antagonists have longer half-lives than substance P itself.
Dose Calculator
Calculate your draw amount for an insulin syringe (U-100)
Draw to the
10
unit mark
Draw 10 units for your 250mcg dose of Substance P Antagonist
This calculator is for educational purposes. Always verify your calculations and consult a healthcare professional.
Where does Substance P Antagonist sit?
See how this peptide compares across all 150 peptides in our database.
Evidence Score
0.65
Potential Side Effects
Substance P Antagonist discussions
Quick Facts
- Administration
- Intra-articular injection in research
- Typical Dose
- Research compounds — clinical studies ongoing
- Frequency
- N/A for peptide antagonists
- References
- 0 curated + 46 from PubMed
- Clinical Trials
- 5 registered
- Evidence Score
- 0.7 / 100
Frequently Asked Questions about Substance P Antagonist
What is Substance P Antagonist?
Substance P antagonist peptides target the neurokinin-1 receptor (NK1R) to reduce joint pain and inflammation. Substance P is a neuropeptide released from sensory nerve fibers in joint tissue that amplifies pain signaling inflammation and cartilage degradation. NK1R antagonists including aprepitant (FDA-approved for chemotherapy-induced nausea) have been studied for osteoarthritis pain with promising results in early trials. Peptide-based NK1R antagonists represent a targeted approach to joint pain that addresses neurogenic inflammation rather than just blocking pain transmission.
How does Substance P Antagonist work?
Substance P is released from CGRP-positive sensory nerve fibers in the synovium and periarticular tissues during joint inflammation and injury. It activates NK1R on multiple cell types in the joint — synoviocytes macrophages mast cells endothelial cells and chondrocytes — promoting a cascade of pro-inflammatory effects including vasodilation plasma extravasation mast cell degranulation and cytokine release. This neurogenic inflammation amplifies the primary inflammatory response and sensitizes joint nociceptors contributing to the central sensitization that characterizes chronic OA pain. NK1R antagonist peptides block these effects reducing neurogenic inflammation and pain sensitization. Intra-articular delivery of NK1R antagonists has shown particular promise in animal models by achieving high local concentrations at the site of pain generation.
What is the recommended dosage for Substance P Antagonist?
The typical dose is Research compounds — clinical studies ongoing. N/A for peptide antagonists. Administration: Intra-articular injection in research. Aprepitant (oral NK1R antagonist) has been studied off-label for OA pain. Peptide-specific NK1R antagonists are in research stage. This entry documents the neurogenic inflammation mechanism in joint pain.
What are the side effects of Substance P Antagonist?
Research compounds — limited data for peptide antagonists. Aprepitant class effects: fatigue hiccups dizziness (uncommon)
Questions reflect common community inquiries. This is not medical advice.